98%
921
2 minutes
20
Exposure to neurotropic viruses, such as herpes simplex virus type 1 and human cytomegalovirus, has been reported to be associated with cognitive impairment in schizophrenia. These viruses have evolved highly sophisticated strategies for decreasing the efficacy of the host immune response and interfering with viral clearance. Particular immunoglobulin GM (γ marker) genotypes modulate these viral immunoevasion strategies, influence antibody responsiveness to viral proteins, and are also associated with susceptibility to schizophrenia, providing an excellent rationale for determining their possible involvement in the cognitive functions in this highly heritable neurodevelopmental disorder. In this investigation, we assessed the cognitive functions (verbal memory, working memory, motor speed, verbal fluency, attention and processing speed, and executive function) in 145 patients with schizophrenia and characterized their DNA for several GM and KM (κ marker) alleles. Particular KM and GM genotypes were significantly associated with verbal memory and attention and processing speed scores, respectively (P = 0.01 and 0.001). Epistatic effects of GM and KM genotypes on attention and processing speed, verbal fluency, and motor speed were also noted (P = 0.031, 0.047, 0.003). These results, for the first time, show that hitherto understudied immunoglobulin GM and KM genotypes-individually and epistatically-contribute to the magnitude of interindividual variability in the cognitive functions in patients with schizophrenia. Additional studies involving these highly polymorphic genes of the immune system are needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750093 | PMC |
http://dx.doi.org/10.1007/s00251-017-1030-6 | DOI Listing |
Ann Med
December 2025
School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: To review the biological functions of ergothioneine (ERGO), its correlation with plasma levels in cognitive frailty, and research progress in treating frailty and cognitive impairment, with the aim of providing a reference for ERGO application in cognitive frailty treatment.
Methods: A comprehensive review of existing literature on ERGO's chemical structure, sources, antioxidant and anti-inflammatory effects, and its role in cognitive frailty was conducted. Clinical trial data and metabolomic studies were also analyzed to understand ERGO's therapeutic potential.
Disabil Rehabil
September 2025
Department of Occupational Therapy, Yonsei University Graduate School, Seoul, South Korea.
Purpose: This study aimed to develop a tailored International Classification of Functioning, Disability and Health (ICF) Core Set for driving rehabilitation in South Korea, addressing the functional needs of individuals with disabilities and the gaps in the current rehabilitation system.
Materials And Methods: An initial item pool was created based on focus group interviews with 13 individuals with disabilities who use assistive driving technologies. This was followed by two Delphi rounds with 12 occupational therapy experts.
Disabil Rehabil
September 2025
Occupational Performance Network, Sydney, Australia.
Purpose: Initial studies identified the Perceive, Recall, Plan and Perform Assessment (PRPP-A) as a cognitive assessment with potential for culturally safe use with Aboriginal and Torres Strait Islander peoples with neurocognitive impairments in the Northern Territory of Australia. This study examines construct and concurrent validity of the PRPP-A.
Methods: Data were collected from a medical record review.
Amyotroph Lateral Scler Frontotemporal Degener
September 2025
Faculdade de Medicina, Centro de Estudos Egas Moniz, Universidade de Lisboa, Lisboa, Portugal.
This study aimed to derive standardized regression-based (SRB) reliable change indices (RCIs) for the cognitive section of the Portuguese Edinburgh Cognitive and Behavioral ALS Screen (ECAS-C). Forty-nine MND patients undergoing the ECAS were followed-up (T1) at 7.2 ± 2 months (range = 5-12).
View Article and Find Full Text PDFNeurosci Bull
September 2025
Zhejiang Key Laboratory of Organ Development and Regeneration, College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou, 311121, China.
The neurological manifestations of SHORT syndrome include intrauterine growth restriction, microcephaly, intellectual disability, hearing loss, and speech delay. SHORT syndrome is generally believed to be caused by PIK3R1 gene mutations and impaired PI3K-AKT activation. Recently, a clinical case report described a SHORT syndrome with a novel mutant in PRKCE gene encoding protein kinase Cε (PKCε).
View Article and Find Full Text PDF